MR mammography benefits from the reputation of its cornerstone modality's ability to detect soft-tissue abnormalities, particularly cancer. And it presents the opportunity for patients to avoid the discomfort of breast compression.
MR mammography benefits from the reputation of its cornerstone modality's ability to detect soft-tissue abnormalities, particularly cancer. And it presents the opportunity for patients to avoid the discomfort of breast compression.
But MR mammography also faces challenges. Suspicious lesions that are defined on a breast MR image may require biopsy with guidance. MR breast coils capable of biopsy may not be optimally designed for it, and 1.5T cylindrical systems, which are most commonly used for MR mammography, pose access problems.
To help meet these challenges, Toshiba is extending the clinical reach of its general-purpose 0.35T Ultra MR scanner with software and peripherals that optimize the system for breast MR.
Midfield opens are typically not powerful enough to obtain high-quality images of the breast. But that's not the case for the Ultra, which features gradients that operate at an amplitude of 25 mT/m and slew rate of 100 mT/m/sec, said Dr. John Feller, medical director of Desert Medical Imaging of Palm Springs, CA.
"This is the first time we've had a low-field open MRI that has enough gradient performance to do this type of exam," he said.
Feller is working with Toshiba engineers to develop pulse sequences on the Ultra for contrast-enhanced dynamic MR mammography. He directs activities at three Desert Medical Imaging centers in the Coachella Valley. Patients referred for evaluation of a suspicious lesion seen with x-ray mammography are sent to the center housing a 1.5T MR system. Dynamic imaging, which uses gadolinium-based contrast to highlight suspicious breast lesions, requires high temporal as well as spatial resolution. Feller would prefer to use an open system for those exams, as the increased comfort reduces the risk of patient movement.
"We frequently will subtract the post- from the pregadolinium images," he said. "Subtraction works better if the patient is not moving around."
The pulse sequences being developed by Feller and Toshiba engineers will optimize the visualization of contrast using a software package called CADstream. Toshiba is also developing its own custom-made breast coil for use on the Ultra. It is not locked into using just this coil design, however. Another coil that has caught the company's eye is being developed by Confirma of Kirkland, WA, the maker of CADstream.
The coil, which supports breast biopsy with unprecedented flexibility, is now in clinical testing. The multichannel, phased-array coil allows lateral, medial, and cranio-caudal interventions.
"Being able to reach any posterior, lateral lesion is important," said Sara Larsen, Confirma product manager.
Confirma expects to begin marketing its new coil by early spring. Toshiba's optimized breast package could be available as early as midsummer.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.